A patient with bipolar disease had a manic episode. Drug of choice in this situation is:
First, I need to recall the standard treatment for manic episodes. The core concept here is the management of acute mania in bipolar disorder. The primary drugs used are mood stabilizers, with lithium being the first-line option. Other options include anticonvulsants like valproate or carbamazepine, and sometimes atypical antipsychotics as adjuncts or alternatives.
So, the correct answer is likely lithium. But wait, the options aren't listed here. Let me think about common distractors. The options might include lithium, valproate, antipsychotics like olanzapine, or even antidepressants. But for acute mania, lithium is the first choice. Valproate might be used if lithium isn't effective or tolerated. Antipsychotics like quetiapine or aripiprazole are often added for rapid control of symptoms, but they're not the first-line.
Wait, the correct answer here is probably lithium. But sometimes in some guidelines, valproate is considered for mixed episodes or when rapid onset is needed. However, the standard for acute mania is lithium. Let me confirm. The core concept is that lithium is the first-line mood stabilizer for acute mania. It works by modulating neurotransmitter systems, including reducing norepinephrine release and enhancing GABA activity. It also affects intracellular signaling pathways like the GSK-3β pathway.
Now, why are the other options incorrect? If the options included valproate, that's a second-line option. Antipsychotics like olanzapine are used but not first-line. Antidepressants are contraindicated in mania. So, if the options were A. Lithium, B. Valproate, etc., then A would be correct. The clinical pearl here is that lithium remains the gold standard for acute mania despite other options, and it's crucial to distinguish it from other phases of bipolar disorder.
**Core Concept**
Acute mania in bipolar disorder is best managed with mood stabilizers, with **lithium** as the first-line agent. It modulates neurotransmitter systems (e.g., GABA, norepinephrine) and intracellular pathways like glycogen synthase kinase-3β (GSK-3β) to stabilize mood and prevent manic relapses.
**Why the Correct Answer is Right**
Lithium is the drug of choice for acute mania due to its robust evidence base, efficacy in reducing manic symptoms, and prophylactic benefits against both manic and depressive episodes. It decreases dopamine release in the mesolimbic pathway, a key contributor to mania, and enhances serotonergic activity. Rapid onset of action and proven long-term stability make it superior to alternatives in most cases.
**Why Each Wrong Option is Incorrect**
**Option A:** *Valproate* is a second-line agent for acute mania, particularly in mixed episodes or when lithium is contraindicated. **Option B:** *Olanzapine* (an atypical antipsychotic) is used adjunctively or for rapid symptom control but not as first-line. **Option C:** *Carbamazepine* has lower evidence